Clinical Evidence & Dosing Differences: What Trials Reveal
UK Weight Loss Results: Wegovy Dose Compared to Mounjaro Trial Evidence
When evaluating Wegovy dose compared to Mounjaro for weight management, UK patients benefit from robust clinical trial data for both treatments. Wegovy's STEP programme demonstrated that patients taking semaglutide alongside a reduced-calorie diet and increased physical activity achieved ~15% average weight loss at 68 weeks (Wilding et al., NEJM, 2021). The SELECT trial further revealed a 20% reduction in major cardiovascular events with Wegovy treatment. Mounjaro's SURMOUNT trials showed promising results with tirzepatide's dual GIP/GLP-1 mechanism, though direct head-to-head comparisons aren't available due to different trial designs and populations.
Understanding these results requires recognising that both treatments work through distinct pathways whilst requiring lifestyle modifications for optimal outcomes. Wegovy acts as a GLP-1 receptor agonist, mimicking natural fullness hormones, whereas Mounjaro targets both GIP and GLP-1 receptors for potentially enhanced metabolic effects. UK prescribers at EverydayMeds evaluate individual patient factors when determining which prescription-only medicine may be more suitable for specific weight management goals.
Wegovy Dose Compared to Mounjaro: Pricing and Value Analysis
Cost considerations often influence treatment choice when comparing Wegovy dose schedules to Mounjaro options. Wegovy pricing at EverydayMeds starts from £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our bundles provide convenient multi-month supply options, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99 or the Ultimate Stability Trio (three 2.4mg pens) for £649.99. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive rates.
Mounjaro pricing follows a different structure due to its distinct dose escalation schedule and pen delivery system. Both treatments require ongoing commitment, as STEP 1 extension data showed patients regained approximately two-thirds of weight lost within one year of stopping Wegovy treatment. This underscores the importance of viewing either option as a long-term weight management strategy rather than a short-term solution. EverydayMeds provides both treatments through the same streamlined process, allowing prescribers to recommend the most cost-effective option based on individual patient circumstances.
STEP Trial Evidence: Wegovy Dose Compared to Mounjaro Clinical Outcomes
The comprehensive STEP programme provides substantial evidence for Wegovy's effectiveness across different populations and durations. STEP 2 demonstrated ~clinically studied weight loss in patients with type 2 diabetes, whilst STEP 3 achieved ~16% when combined with intensive behavioural therapy. STEP 5's two-year data showed sustained ~clinically studied weight loss, indicating durability of response with continued treatment.
Mounjaro's SURMOUNT trials evaluated tirzepatide across similar timeframes, though direct statistical comparisons between trials aren't appropriate due to different study designs, patient populations, and endpoints. Both treatments represent significant advances in prescription weight management, with mechanisms that address appetite regulation and metabolic function through incretin pathways.
How Wegovy Works: GLP-1 Mechanism vs Mounjaro's Dual Action
Understanding the mechanistic differences helps explain why Wegovy dose compared to Mounjaro may produce varying responses in different patients. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone GLP-1 released after eating. This action reduces appetite by slowing gastric emptying, promoting satiety after smaller meals, and potentially reducing food cravings through effects on brain appetite centres. The once-weekly injection provides consistent hormone levels, supporting sustained appetite regulation throughout the week. Wegovy's mechanism has been extensively studied in the STEP programme, demonstrating effectiveness when combined with lifestyle modifications.
EverydayMeds Ordering Process: From Assessment to Delivery
Accessing either Wegovy or Mounjaro through EverydayMeds follows our streamlined three-step process designed for patient convenience and clinical safety. The initial online clinical assessment takes approximately three minutes, covering medical history, current medications, weight management goals, and contraindications. Our prescribers review applications within standard three working days or express 24-hour service for urgent cases. Once approved, next-day delivery utilises cold-chain transportation maintaining 2-8°C temperature control throughout transit. This process ensures both treatments reach patients in optimal condition whilst meeting all MHRA requirements for prescription-only medicine supply.
Storage and Practical Considerations: Wegovy vs Mounjaro Differences
Practical storage differences often influence patient preference when comparing Wegovy dose to Mounjaro options. Wegovy pens remain stable in the fridge at 2-8°C and can withstand up to six weeks at room temperature below 30°C once removed from refrigeration. Mounjaro requires similar refrigerated storage but has a shorter room temperature tolerance of 21 days, potentially limiting travel flexibility. Both treatments use pre-filled injection pens with different mechanisms — Wegovy's FlexTouch system vs Mounjaro's KwikPen design. The dose escalation schedules also differ, with Wegovy following a five-stage progression over 16 weeks compared to Mounjaro's alternative timeline, affecting treatment planning and pen supply requirements.
UK Market Analysis: Wegovy Dose Compared to Mounjaro Availability and Access
The UK weight management landscape has evolved significantly with both Wegovy and Mounjaro receiving MHRA approval for obesity treatment. NICE guidance TA875 recommends Wegovy with specialist weight management support, establishing it within NHS pathways for eligible patients. Private access through regulated pharmacies like EverydayMeds (GPhC #9012878) ensures wider availability for patients meeting clinical criteria. Market demand often influences supply chains, with both manufacturers working to maintain consistent stock levels across UK healthcare providers.
Patient choice between these treatments increasingly depends on individual response patterns, tolerability profiles, and practical factors like injection frequency and storage requirements. EverydayMeds maintains stock of both options, allowing prescribers flexibility in treatment selection based on patient-specific factors rather than availability constraints. This comprehensive approach ensures optimal matching between patient needs and treatment characteristics.
Making Your Choice: Wegovy Dose Compared to Mounjaro Prescriber Guidance
Both Wegovy and Mounjaro represent evidence-based approaches to prescription weight management, each with distinct advantages depending on individual patient circumstances. EverydayMeds prescribers evaluate factors including medical history, current medications, lifestyle patterns, and treatment preferences when recommending between these options. Our clinical team stays current with emerging research and real-world evidence to provide informed guidance. Whether you choose Wegovy's established STEP trial evidence or Mounjaro's dual-receptor approach, ongoing support ensures optimal treatment outcomes. Begin your assessment today using discount codes FIRST40 for new customers or DOSE25 for returning patients, with next-day delivery ensuring prompt treatment initiation once approved.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
